Tower Research Capital (TRC)’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $293K | Sell |
11,393
-9,585
| -46% | -$197K | 0.01% | 1404 |
|
|
2026
Q1 | $403K | Buy |
20,978
+8,037
| +62% | +$160K | 0.01% | 1076 |
|
|
2025
Q4 | $214K | Buy |
12,941
+5,565
| +75% | +$93.9K | 0.01% | 1388 |
|
|
2025
Q3 | $107K | Sell |
7,376
-6,293
| -46% | -$90.4K | ﹤0.01% | 1934 |
|
|
2025
Q2 | $191K | Buy |
13,669
+10,457
| +326% | +$147K | 0.01% | 1820 |
|
|
2025
Q1 | $43.7K | Sell |
3,212
-8,076
| -72% | -$155K | ﹤0.01% | 2321 |
|
|
2024
Q4 | $230K | Buy |
11,288
+10,857
| +2,519% | +$278K | ﹤0.01% | 1622 |
|
|
2024
Q3 | $12.6K | Sell |
431
-20,401
| -98% | -$506K | ﹤0.01% | 3576 |
|
|
2024
Q2 | $484K | Buy |
20,832
+19,407
| +1,362% | +$373K | 0.01% | 1375 |
|
|
2024
Q1 | $29.2K | Sell |
1,425
-4,299
| -75% | -$80.8K | ﹤0.01% | 2672 |
|
|
2023
Q4 | $123K | Buy |
5,724
+4,016
| +235% | +$79.5K | ﹤0.01% | 2482 |
|
|
2023
Q3 | $35.2K | Sell |
1,708
-4,282
| -71% | -$109K | ﹤0.01% | 2874 |
|
|
2023
Q2 | $177K | Buy |
5,990
+1,985
| +50% | +$55.8K | 0.01% | 1643 |
|
|
2023
Q1 | $92K | Buy |
4,005
+2,451
| +158% | +$67.5K | ﹤0.01% | 1943 |
|
|
2022
Q4 | $44K | Sell |
1,554
-12,662
| -89% | -$377K | ﹤0.01% | 2447 |
|
|
2022
Q3 | $437K | Buy |
14,216
+3,700
| +35% | +$120K | 0.01% | 1252 |
|
|
2022
Q2 | $309K | Buy |
10,516
+8,419
| +401% | +$221K | 0.01% | 1457 |
|
|
2022
Q1 | $68K | Sell |
2,097
-5,242
| -71% | -$180K | ﹤0.01% | 2487 |
|
|
2021
Q4 | $328K | Buy |
7,339
+1,924
| +36% | +$91.2K | 0.01% | 1413 |
|
|
2021
Q3 | $273K | Buy |
5,415
+888
| +20% | +$50K | 0.01% | 1508 |
|
|
2021
Q2 | $355K | Sell |
4,527
-3,135
| -41% | -$194K | 0.01% | 1459 |
|
|
2021
Q1 | $437K | Buy |
7,662
+3,625
| +90% | +$243K | 0.01% | 1353 |
|
|
2020
Q4 | $338K | Buy |
4,037
+1,731
| +75% | +$105K | 0.01% | 1305 |
|
|
2020
Q3 | $83K | Sell |
2,306
-7,275
| -76% | -$219K | ﹤0.01% | 3286 |
|
|
2020
Q2 | $232K | Buy |
+9,581
| New | +$225K | 0.01% | 1667 |
|
|
2019
Q4 | – | Sell |
-2,095
| Closed | -$32K | – | 3707 |
|
|
2019
Q3 | $32K | Buy |
2,095
+1,980
| +1,722% | +$37.8K | ﹤0.01% | 2138 |
|
|
2019
Q2 | $2K | Sell |
115
-713
| -86% | -$16K | ﹤0.01% | 3249 |
|
|
2019
Q1 | $19K | Buy |
828
+721
| +674% | +$15.1K | ﹤0.01% | 2291 |
|
|
2018
Q4 | $2K | Buy |
+107
| New | +$1.94K | ﹤0.01% | 3337 |
|
|
2018
Q3 | – | Sell |
-3,668
| Closed | -$56K | – | 3859 |
|
|
2018
Q2 | $56K | Buy |
+3,668
| New | +$69.1K | ﹤0.01% | 1784 |
|
Other funds holding DNLI
Tower Research Capital (TRC)'s DNLI Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Denali Therapeutics (DNLI) stake by 46% in Q2 2026, selling an estimated $197K and leaving 11,393 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #1404.
Tower Research Capital (TRC) first reported a position in DNLI in Q2 2018 and has held it in 30 quarters since. The position peaked at $484K in Q2 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Tower Research Capital (TRC) held 11,393 shares of Denali Therapeutics worth $293K as of Q2 2026.
- Tower Research Capital (TRC) sold 9,585 Denali Therapeutics shares in Q2 2026, an estimated $197K.
- Denali Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1404 holding.
- Tower Research Capital (TRC) first reported a position in Denali Therapeutics in Q2 2018 and has held it in 30 quarters since.
- Tower Research Capital (TRC)'s Denali Therapeutics position peaked at $484K in Q2 2024.
- 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.